Latest On Eisai Co., Ltd (ESALF):
About Eisai Co., Ltd (ESALF):
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
General
- Name Eisai Co., Ltd
- Symbol ESALF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 10,998
- Fiscal Year EndMarch
- Web URLhttp://www.eisai.co.jp
Valuation
- Trailing PE 34.36
- Forward PE 27.7
- Price/Sales (Trailing 12 Mt.) 3.16
- Price/Book (Most Recent Quarter) 3.33
- Enterprise Value Revenue 0.03
- Enterprise Value EBITDA 0.13
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.77
- Next Year EPS Estimate $2.57
- Profit Margin 13%
- Return on Assets 6%
- Return on Equity 14%
- Earnings Per Share $2.08
- Revenue Per Share $0
- Gross Profit 519.93 billion
- Quarterly Earnings Growth -3%
ESG Rating
Highlights
- Market Capitalization 20.03 billion
- PEG Ratio 244930
- Analyst Target Price $91.82
- Book Value Per Share $19.95
Share Statistics
- Shares Outstanding 286.58 million
- Shares Float 285.78 million
- % Held by Insiders 917%
- % Held by Institutions 37.94%
Technicals
- Beta 0.48
- 52 Week High $90.35
- 52 Week Low $22
- 50 Day Moving Average 72.3
- 200 Day Moving Average 76.63
Dividends
- Forward Annual Dividend Rate $1.49
- Forward Annual Dividend Yield 2.09%
- Payout Ratio 105%
- Dividend Date 2018-05-24
- ExDividend Date 2021-03-30
- Dividend Per Share $1.36
- Dividend Yield 0%
Eisai Co., Ltd (ESALF) Dividend Calendar:
ESALF's last dividend payment was made to shareholders on May 24, 2018.
Eisai Co., Ltd pays out 105% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Eisai Co., Ltd (ESALF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2020-12-31 | $N/A | $0.65 | ||
2020-09-30 | 2020-12-31 | $N/A | $0.65 | ||
2020-06-30 | 2020-09-30 | $N/A | $0.05 | $42.20 | -99.89% |
2020-03-31 | 2020-06-30 | $N/A | $0.79 | ||
2019-12-31 | 2020-03-31 | $1.72 billion | $1.57 | ||
2019-09-30 | 2019-12-31 | $1.34 billion | $1.49 | $63.85 | -97.67% |
2019-06-30 | 2019-09-30 | $1.42 billion | $0.17 | ||
2019-03-31 | 2019-06-30 | $1.58 billion | $0.70 | ||
2018-12-31 | 2019-03-31 | $1.43 billion | $0.74 | ||
2018-09-30 | 2018-12-31 | $1.38 billion | $0.23 | ||
2018-06-30 | 2018-09-30 | $1.38 billion | $0.62 | $36.30 | -98.28% |
2018-03-31 | 2018-06-30 | $1.51 billion | $0.39 | $96.80 | -99.6% |
2017-12-31 | 2018-03-31 | $1.37 billion | $0.78 | $36.70 | -97.88% |
2017-09-30 | 2017-12-31 | $1.27 billion | $0.29 | $24.20 | -98.81% |
2017-06-30 | 2017-09-30 | $1.26 billion | $0.28 | $24.90 | -98.88% |
2017-03-31 | 2017-06-30 | $129.87 billion | $0.30 | ||
2016-12-31 | 2017-03-31 | $0.03 | $30.50 | -99.9% | |
2016-09-30 | 2016-12-31 | $0.31 | $12.90 | -97.57% | |
2016-06-30 | 2016-09-30 | $0.28 | $32.65 | -99.14% | |
2016-03-31 | 2016-06-30 | $0.67 | $8.40 | -92.01% | |
2015-12-31 | 2016-03-31 | $0.52 | $21.80 | -97.63% | |
2015-09-30 | 2015-12-31 | $0.79 | |||
2015-06-30 | 2015-09-30 | $0.16 | $9.50 | -98.29% | |
2015-03-31 | 2015-06-30 | $0.16 | |||
2014-12-31 | 2015-03-31 | $0.19 | $24.00 | -99.21% | |
2014-09-30 | 2014-12-31 | $0.77 | $28.50 | -97.31% | |
2014-06-30 | 2014-09-30 | $0.15 | $20.30 | -99.26% | |
2014-03-31 | 2014-06-30 | $0.20 | $54.70 | -99.64% | |
2013-12-31 | 2014-03-31 | $0.12 | $50.30 | -99.77% | |
2013-09-30 | 2013-12-31 | $0.06 | |||
2013-06-30 | 2013-09-30 | $0.65 | |||
2013-03-31 | 2013-06-30 | $0.33 | |||
2012-12-31 | 2013-03-31 | $0.53 | |||
2012-09-30 | 2012-12-31 | $0.39 | |||
2012-06-30 | 2012-09-30 | $0.57 | |||
2012-03-31 | 2012-06-30 | $0.52 | |||
2011-12-31 | 2012-03-31 | $0.40 | |||
2011-09-30 | 2011-12-31 | $0.72 | |||
2011-06-30 | 2011-09-30 | $0.90 | |||
2011-03-31 | 2011-06-30 | $0.59 | |||
2010-12-31 | 2011-03-31 | $0.00 | |||
2010-09-30 | 2010-12-31 | $1.19 | |||
2010-06-30 | 2010-06-30 | $0.72 |
Eisai Co., Ltd (ESALF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Eisai Co., Ltd (ESALF) Chart:
Eisai Co., Ltd (ESALF) News:
Below you will find a list of latest news for Eisai Co., Ltd (ESALF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Eisai Co., Ltd (ESALF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Eisai Co., Ltd (ESALF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|